Acute Myeloid Leukemia Resources

The following resources may be helpful in considering participation in a clinical trial and learning more about new treatment options for relapsed acute myeloid leukemia (AML) or refractory AML.

Be The Match Foundation is a global leader in bone marrow transplantation. Be The Match conducts research to improve transplant outcomes provide support and resources for patients, and partner with a global network.

The Leukemia & Lymphoma Society is at the forefront of the fight to cure cancer. LLS is the largest nonprofit dedicated to creating a world without blood cancers. Since 1949, LLS has invested nearly $1.3 billion in groundbreaking research, pioneering many of today’s most innovative approaches.

The Leukemia Research Foundation is dedicated to conquering all blood cancers by funding research into their causes and cures, and enriching the quality of life of those touched by these diseases.

National Organization for Rare Disorders (NORD) is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 300 patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.

CancerCare® is the leading national organization dedicated to providing free, professional support services including counseling, support groups, educational workshops, publications and financial assistance to anyone affected by cancer. All CancerCare services are provided by oncology social workers and world-leading cancer experts.

Cancer Support Community: As the largest professionally led nonprofit network of cancer support worldwide, the Cancer Support Community (CSC) is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action, and sustained by community.

RTX‑240 Phase 1/2 Clinical Trial

Complete a patient screener to see if you may be able to participate.

Patient Screener

Patient Screener

Sign up to learn more about Red Cell Therapeutics™ and cancer clinical trials.

Sign Up Form

Sign Up Form

Rubius Therapeutics is now enrolling patients in a phase 1/2 clinical trial of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors, or relapsed acute myeloid leukemia (AML) or refractory AML.

Complete a patient screener to see if you may be able to participate.

Thank you! You may be a potential candidate for a study doctor to evaluate for participation in this study.

If you wish to be connected to a clinical trial site in the RTX-240 study, please fill in your contact information below. Someone from our Patient Advocacy Team may reach out to you to determine your interest and if you would meet the requirements to be evaluated by a study doctor for screening in the RTX-240 study. Your personal information, including information entered below and discussed with our Patient Advocacy Team, may then be shared with a clinical study site.

NEXT

Thank you!

Based on the information provided, you may not meet the requirements for this study. We want to thank you for your interest – patient volunteers and their family members are an essential part of the development of new therapies for cancer. If you still would like to learn more about Red Cell Therapeutics™ and receive updates about clinical trials that might be available in your area for the potential treatment of cancer for yourself or a loved one, sign up here.

Thank you!

You may be a potential candidate for a study doctor to evaluate for participation in this study. If you wish to be connected to a clinical trial site for the RTX-240 study, please fill in your contact information below. Someone from our Patient Advocacy Team may reach out to you to determine if you would meet the requirements to be evaluated by a study doctor for screening for the RTX-240 study. Your personal information, including information entered below and discussed with our Patient Advocacy Team, may then be shared with a clinical study site.